WHO Consults On Draft Q&As To Support 2009 Guide On Evaluation Of Biosimilars
Executive Summary
The Q&A document covers a wide a range of issues, ranging from licensing requirements to pharmacovigilance. However, it does not address interchangeability, switching, substitution, naming and shortages.